Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bisphosphonates for metastatic bone pain.

Perry G Fine1, Cassandra Bellamy

  • 1Department of Anesthesiology, School of Medicine, University of Utah, Suite 200, 615 Arapeen Drive, Salt Lake City, UT 84132, USA. fine@aros.net

Journal of Pain & Palliative Care Pharmacotherapy
|October 13, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Penicillin allergy evaluation in hospitalized patients with hematologic malignancy.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2023
Same author

Predictors of Cisatracurium Continuous Infusion Dose in Acute Respiratory Distress Syndrome.

Journal of pharmacy practice·2019
Same author

Opioid utilization patterns among patients with cancer and non-cancer pain.

Journal of opioid management·2019
Same author

A Systematic Assessment and Monitoring Intervention to Improve Pain Management and Quality Reporting Among Home Hospice Patients.

Journal of pain and symptom management·2018
Same author

Hospice Underutilization in the U.S.: The Misalignment of Regulatory Policy and Clinical Reality.

Journal of pain and symptom management·2018
Same author

Impact of opioid-induced constipation on healthcare resource utilization and costs for cancer pain patients receiving continuous opioid therapy.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2018
Same journal

Systemic Amyloidosis: A Clinical Challenge from the Palliative Care Perspective.

Journal of pain & palliative care pharmacotherapy·2026
Same journal

Cancer Patients with Neuropathic Pain: Pharmacist-Led Recommendation and Management and Mirogabalin Outcomes in a Single-Center Retrospective Observational Cohort.

Journal of pain & palliative care pharmacotherapy·2026
Same journal

Cost-Effectiveness of Integrative Pain Management for Chronic Pain: A Systematic Review of Economic Evaluation.

Journal of pain & palliative care pharmacotherapy·2026
Same journal

High-Dose Monotherapy or Combination Therapy in Neuropathic Pain: A Necessary Reflection.

Journal of pain & palliative care pharmacotherapy·2026
Same journal

The Price of Goodbye.

Journal of pain & palliative care pharmacotherapy·2026
Same journal

In the End, What Shall We Say?

Journal of pain & palliative care pharmacotherapy·2026
See all related articles

Newer bisphosphonates effectively manage cancer pain from bone metastases. This review compares the pharmacokinetics of these important pain management drugs.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Bisphosphonates are increasingly utilized for managing pain associated with bony metastases in cancer patients.
  • Bone metastases represent a significant source of pain and morbidity in advanced cancer.

Purpose of the Study:

  • To review newer bisphosphonates used for managing pain from bony metastases.
  • To compare the pharmacokinetic properties of these agents.

Main Methods:

  • Literature review of newer bisphosphonate agents.
  • Comparative analysis of pharmacokinetic data.

Main Results:

  • Identification of key newer bisphosphonate agents.
  • Comparison of absorption, distribution, metabolism, and excretion profiles.

Related Experiment Videos

  • Discussion of factors influencing pharmacokinetic variability.

    • Conclusions:

    • Newer bisphosphonates offer improved efficacy in managing pain from bone metastases.
    • Understanding pharmacokinetic differences is crucial for optimizing treatment and patient outcomes.